These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 12900302)

  • 1. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
    Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
    J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
    Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
    Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
    Stone JM; Bressan RA; Erlandsson K; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2005 Aug; 180(4):664-9. PubMed ID: 15719226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Visvikis D; Ell PJ; Stephenson C; Kerwin RW; Pilowsky LS
    Br J Psychiatry; 1999 Sep; 175():231-8. PubMed ID: 10645324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.
    Stephenson CM; Bigliani V; Jones HM; Mulligan RS; Acton PD; Visvikis D; Ell PJ; Kerwin RW; Pilowsky LS
    Br J Psychiatry; 2000 Nov; 177():408-15. PubMed ID: 11059993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
    Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
    Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
    Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
    Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Loc'H C; Mazière B; Paillère-Martinot ML
    Br J Psychiatry; 2001 Dec; 179():503-8. PubMed ID: 11731352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
    Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
    Neuropsychopharmacology; 2005 Dec; 30(12):2283-9. PubMed ID: 16123775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole.
    Nyberg S; Olsson H; Nilsson U; Maehlum E; Halldin C; Farde L
    Psychopharmacology (Berl); 2002 Jun; 162(1):37-41. PubMed ID: 12107615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.